Astrazeneca Phar

64
Hold
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE203A01020
  • NSEID: ASTRAZEN
  • BSEID: 506820
INR
9,041.50
-185 (-2.01%)
BSENSE

Dec 08

BSE+NSE Vol: 4.07 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024

Compare Profit and Loss Results of Astrazeneca Phar
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
5,285.00
-3,569.00
-67.53%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
5,285.00
-3,569.00
-67.53%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
-84.00
-248.00
-295.24%
Raw Materials Consumed
1,295.00
2,330.00
-1,035.00
-44.42%
Power & Fuel Cost
5.00
131.00
-126.00
-96.18%
Employee Cost
257.00
736.00
-479.00
-65.08%
Operating Expenses
18.00
256.00
-238.00
-92.97%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
253.00
-160.00
-63.24%
Cost of Software developments
0.00
28.00
-28.00
-100.00%
Miscellaneous Expenses
13.00
100.00
-87.00
-87.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
4,245.00
-2,783.00
-65.56%
Operating Profit (PBDIT) excl Other Income
253.00
1,040.00
-787.00
-75.67%
Other Income
40.00
207.00
-167.00
-80.68%
Operating Profit (PBDIT)
294.00
1,247.00
-953.00
-76.42%
Interest
1.00
114.00
-113.00
-99.12%
Profit before Depriciation and Tax
293.00
1,133.00
-840.00
-74.14%
Depreciation
39.00
222.00
-183.00
-82.43%
Profit Before Taxation & Exceptional Items
253.00
911.00
-658.00
-72.23%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
911.00
-755.00
-82.88%
Provision for Tax
40.00
219.00
-179.00
-81.74%
Profit After Tax
115.00
691.00
-576.00
-83.36%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
1,359.00
-781.00
-57.47%
Profit Available for appropriations
693.00
2,050.00
-1,357.00
-66.20%
Appropriations
693.00
2,050.00
-1,357.00
-66.20%
Equity Dividend (%)
1600%
1.4%
1,598.60
Earnings Per Share
46.3
5.22
41.08
786.97%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024

Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024